Speciality Medicines Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Speciality Medicines Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $217.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Speciality Medicines Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $217.1K Trade | TransData Nexus

Speciality Medicines Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $217.1K Total Trade · DGFT Verified

Speciality Medicines Private Limited is an Indian pharmaceutical exporter with a total trade value of $217.1K across 4 products in 2 therapeutic categories. Based on 32 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Pembrolizumab ($159.8K), Nivolumab ($27.8K), Osimertinib ($27.8K).

Speciality Medicines Private Limited — Export Portfolio & Destination Treemap

Speciality Medicines Private Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Speciality Medicines Private Limited? — Company Overview & Market Position

Speciality Medicines Private Limited (SMPL) is a pharmaceutical company based in Ahmedabad, Gujarat, India. Incorporated on February 5, 2021, under the Corporate Identification Number (CIN) U85300GJ2021PTC120022, SMPL operates as a private limited company. The company is owned by directors Sumit Babubhai Goyani and Parthkumar Babulal Goyani. Its registered office is located at H-401, Silver Stroke Apartment, Bopal, Ahmedabad, Gujarat, 380058, India. SMPL specializes in the wholesale trading and export of pharmaceutical products, focusing on specialty medicines. The company has experienced significant growth, with an annual turnover ranging between ₹25 to ₹100 crore, and employs between 26 to 50 people. In June 2024, SMPL transitioned from a private limited to a public limited company, adopting the name Speciality Medicines Limited.

What Does Speciality Medicines Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Pembrolizumab$159.8K 2Nivolumab

Product Portfolio — Top 4 by Export Value

Speciality Medicines Private Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Pembrolizumab	Advanced Oncology	$159.8K	19	8.3%	6
2	Nivolumab	Advanced Oncology	$27.8K	6	1.2%	8
3	Osimertinib	Advanced Oncology	$27.8K	4	2.5%	7
4	Catheter	Medical Devices & Diagnostics	$1.8K	3	1.6%	7

Speciality Medicines Private Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $217.1K. The top category is Advanced Oncology (99.2% of portfolio), followed by Medical Devices & Diagnostics (0.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Speciality Medicines Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SMPL operates state-of-the-art manufacturing facilities across multiple locations in India. These facilities are WHO-GMP certified, ensuring adherence to global quality standards. The company specializes in the production of oral solids, liquid formulations, specialty products, creams, and ointments. Additionally, SMPL maintains modern, temperature-controlled warehouses in various regions, including India and Africa, to support its distribution and export operations.

3Key Leadership

The leadership team at SMPL is headed by Managing Director Parth Goyani, who has been instrumental in the company's strategic direction and growth. The Chief Financial Officer (CFO) and other key executives are not publicly disclosed. The company's board of directors includes Sumit Babubhai Goyani and Parthkumar Babulal Goyani, who play pivotal roles in overseeing operations and strategic initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Speciality Medicines Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SMPL has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds WHO-GMP certification, which facilitates market access in these regions. While specific regulatory filings and approvals in these markets are not publicly disclosed, SMPL's adherence to international quality standards positions it favorably for market entry and compliance.

2Emerging Markets

SMPL has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its credibility and facilitates access to these regions. SMPL exports to over 23 countries, including Sri Lanka, the United Kingdom, Myanmar, Saudi Arabia, and Ethiopia, indicating a robust presence in these emerging markets.

3Geographic Strategy

SMPL's geographic strategy demonstrates a diversified approach, with exports to over 23 countries across Africa, Europe, the Middle East, and Southeast Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The strategic direction focuses on expanding market presence and enhancing global distribution capabilities.

Speciality Medicines Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding SMPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's WHO-GMP certification suggests compliance with international manufacturing standards, which is a prerequisite for FDA approvals.

2WHO & EU GMP

SMPL holds WHO-GMP certification, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is recognized by the European Union and facilitates market access in EU member states. Specific details regarding EU GMP certificates and EDQM status are not publicly disclosed.

3CDSCO & Indian Regulatory

SMPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

Speciality Medicines Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SMPL operates in a competitive pharmaceutical market, with key competitors including AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. While specific market share comparisons are not publicly available, SMPL's focus on specialty medicines and adherence to international quality standards position it as a competitive player in the industry.

2Key Differentiators

SMPL's key differentiators include its WHO-GMP certification, which ensures compliance with international manufacturing standards, and its diversified product portfolio encompassing oncology, neurology, cardiology, anti-virals, hepatitis, antifungals, injections, life-saving medicines, and vaccines. The company's modern, temperature-controlled warehouses and global distribution network further enhance its competitive advantage.

3Strategic Position

SMPL's current strategic direction focuses on the wholesale trading and export of specialty medicines, with an emphasis on oncology, neurology, cardiology, and other therapeutic areas. The company's future outlook includes expanding its global presence, enhancing manufacturing capabilities, and exploring opportunities in biosimilars and contract development and manufacturing organizations (CDMO) to diversify its portfolio and revenue streams.

Buyer Due Diligence Brief — Evaluating Speciality Medicines Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SMPL has demonstrated a strong track record in the pharmaceutical industry, with an annual turnover ranging between ₹25 to ₹100 crore and employing between 26 to 50 people. The company's adherence to WHO-GMP standards and its diversified product portfolio indicate reliability and consistency in its operations. SMPL's global distribution network and modern, temperature-controlled warehouses further underscore its commitment to quality and customer satisfaction.

2Certifications to Verify

Importers should verify the following certifications when considering SMPL as a supplier:

WHO-GMP Certification: Ensures compliance with international manufacturing standards. Verification can be obtained by contacting the World Health Organization or reviewing the company's official documentation.

EU GMP Certification: Facilitates market access in EU member states. Verification can be obtained by contacting the European Medicines Agency or reviewing the company's official documentation.

Frequently Asked Questions — Speciality Medicines Private Limited

How many pharmaceutical products does Speciality Medicines Private Limited export from India?

Speciality Medicines Private Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Pembrolizumab ($159.8K), Nivolumab ($27.8K), Osimertinib ($27.8K), Catheter ($1.8K). Total export value is $217.1K.

What is Speciality Medicines Private Limited's total pharmaceutical export value?

Speciality Medicines Private Limited's total pharmaceutical export value is $217.1K, based on 32 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Speciality Medicines Private Limited cover?

Speciality Medicines Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (99.2%, 3 products), Medical Devices & Diagnostics (0.8%, 1 products).

Get Full Speciality Medicines Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.